The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Development of Liposomal Ciprofloxacin to Treat Lung Infections
Open accessAbstract
Except for management of Pseudomonas aeruginosa (PA) in cystic fibrosis, there are no approved inhaled antibiotic treatments for any other diseases or for infections from other pathogenic microorganisms such as tuberculosis, non-tuberculous mycobacteria, fungal infections or potential inhaled biowarfare agents including Francisella tularensis, Yersinia pestis and Coxiella burnetii (which cause pneumonic tularemia, plague and Q fever, respectively). Delivery of an antibiotic formulation via the inhalation route has the potential to provide high concentrations at the site of infection with reduced systemic exposure to limit side effects. A liposomal formulation may improve tolerability, increase compliance by reducing the dosing frequency, and enhance penetration of biofilms and treatment of intracellular infections. Two liposomal ciprofloxacin formulations (Lipoquin® and Pulmaquin®) that are in development by Aradigm Corporation are described here.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection
Wong, J. P., Yang, H., Blasetti, K. L., Schnell, G., Conley, J., & Schofield, L. N. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(03)00358-4 · Cited by 153 · cited 12×
“To that end, inhaled formulations of amikacin [23–25] and ciprofloxacin [26–28] are using liposomes that are able to penetrate sputum and biofilm [29] and be phagocytosed by macrophages that harbor NTM infections.”
BackgroundInfluentialRegional lung deposition of nebulized liposome-encapsulated ciprofloxacin
Finlay, W. H., & Wong, J. P. (1998) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(98)00055-6 · Cited by 51 · cited 1×
“The other two nebulizers were selected to test the robustness of Lipoquin because they were used previously for an unrelated liposomal ciprofloxacin formulation and found to disrupt liposomal ciprofloxacin preparation causing extensive drug leakage following nebulization [44].”
Background
Cited by
Targeting microbial biofilms: current and prospective therapeutic strategies
Koo, H., Allan, R. N., Howlin, R. P., Stoodley, P., & Hall-Stoodley, L. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.99 · Cited by 1,800
Antibiotics and Bacterial Resistance—A Short Story of an Endless Arms Race
Baran, A., Kwiatkowska, A., & Potocki, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065777 · Cited by 300
Li, T., Nowell, C. J., Cipolla, D., Rades, T., & Boyd, B. J. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b01308 · Cited by 57
Metadata
- Authors
- Cipolla, D., Blanchard, J., & Gonda, I.
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2016-03-01
- Volume
- 8
- Issue
- 1
- Pages
- 6
- ISSN
- 1999-4923 (ISSN-L)
- OpenAlex
- W2288730971
- Cited by
- 177
- References
- 2
- FWCI
- 19.07
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.